Drug Profile
Granisetron long acting depot - Camurus
Alternative Names: CAM-2047Latest Information Update: 03 Jul 2023
Price :
$50
*
At a glance
- Originator Camurus
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Chemotherapy-induced nausea and vomiting
Most Recent Events
- 03 Jul 2023 Granisetron long acting depot is still in phase I trials for chemotherapy-induced nausea and vomiting in Sweden (Camurus pipeline, July 2023)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Chemotherapy-induced-nausea-and-vomiting in Sweden (SC, Controlled release)
- 09 Apr 2020 Phase-I development is ongoing for Chemotherapy-induced nausea and vomiting in Sweden (Camurus pipeline, April 2020)